Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy-Reference-Cited by-同舟云学术

Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy

Published:2007-01 Issue:4 Volume:7 Page:286-290
ISSN:1557-9190
Container-title:Clinical Lymphoma and Myeloma
language:en
Short-container-title:Clinical Lymphoma and Myeloma

Author:

Hatjiharissi Evdoxia,Hansen Mark,Santos Daniel Ditzel,Xu Lian,Leleu Xavier,Dimmock Elizabeth W.,Ho Allen W.,Hunter Zachary R.,Branagan Andrew R.,Patterson Christopher J.,Kortsaris Alexandros,Verselis Sigitas,Fox Edward,Treon Steven P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference25 articles.

1. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets;Clynes;Nat Med,2000

2. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors;Sampson;Proc Natl Acad Sci USA,2000

3. A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection;Yoneto;J Immunol,2001

4. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas;Manches;Blood,2003

5. The polymorphic Fc gamma receptor II gene maps to human chromosome 1q;Grundy;Immunogenetics,1989

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploratory Study on the Relationship Between FcγRIIIa Gene Polymorphisms and the Efficacy and Toxicity of Rituximab in the Treatment of Stage I/II Diffuse Large B-Cell Lymphoma;Journal of Biomaterials and Tissue Engineering;2019-05-01

2. Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease;Frontiers in Immunology;2019-03-21

3. Genetics in Lymphomagenesis;Neoplastic Diseases of the Blood;2017-09-09

4. The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis;Annals of Hematology;2016-07-19

5. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab;BioDrugs;2016-04-06